A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

@article{Bello2013API,
  title={A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers},
  author={Carlo L. Bello and Evan B Smith and Ana Ruiz-Garcia and Grace Ni and Christine W. Alvey and Cho-Ming Loi},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2013},
  volume={72},
  pages={379-385}
}
This study aimed to characterize the primary routes of elimination of the pan-HER tyrosine kinase inhibitor, dacomitinib (PF-00299804), to evaluate the pharmacokinetics of total radioactivity and of dacomitinib and to identify the metabolites of dacomitinib in plasma, urine, and feces in the healthy volunteers. Six male healthy volunteers (mean age 31.5 years) received a single 45-mg oral dose containing ~100 μCi [14C] dacomitinib. Whole blood, urine, and fecal samples were collected throughout… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

University of Groningen Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer , a review of the literature

A. Saberb, T. J. N. Hiltermanna, K. Kokc, A. van den Bergb, H. J. M. Groena
2017
View 1 Excerpt
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 4 Excerpts
Highly Influenced

Preliminary activity and safety results from a phase I clinical trial of dacomitinib, an irreversible pan-HER inhibitor, in patients with NSCLC

PA Jänne, JH Schellens, JA Engelman
J Clin Oncol 26(15S) (abstr • 2008
View 4 Excerpts
Highly Influenced

Clinical pharmacokinetics of tyrosine kinase inhibitors

M Scheffler, P Di Gion, O Doroshyenko
Focus on 4-anilinoquinazolines. Clin Pharmacokinet • 2011
View 1 Excerpt

Efficacy and safety of PF 299804 versus erlotinib : a global , randomized phase II trial in patients with advanced non - small cell lung cancer after failure of chemotherapy

SS Ramalingam, MJ Boyer, K Park
2010

Antitumor activity and pharmacokinetic properties of dacomitinib , a second - generation irreversible pan - erbB receptor tyrosine kinase inhibi

AJ Gonzales, KE Hook, IW Althaus
Mol Cancer Ther • 2008

Antitumor activity and pharmacokinetic properties of dacomitinib, a secondgeneration irreversible pan-erbB receptor tyrosine kinase inhibitor

AJ Gonzales, KE Hook, IW Althaus
Mol Cancer Ther • 2008
View 2 Excerpts

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management

TJ JrLynch, ES Kim, B Eaby
Oncologist • 2007

Similar Papers

Loading similar papers…